The global Cell Therapy Technologies Market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4% during the forecast period. Rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are the key factors driving the growth of this market.

China, India, Japan, Korea, and Brazil are emerging markets for cell therapy instruments. These markets boast comparatively lenient standards and government regulations as opposed to developed markets in North America and the EU, and thus offer significant growth potential for providers. However, the high cost of cell-based research and the low success rate is expected to restrain market growth to some extent during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978

Recent Developments:
• In 2018, Thermo Fisher Scientific launched a new series of compact refrigerators.
• In 2018, Thermo Fisher Scientific launched an advanced laboratory management system for data integrity and complete regulatory compliance.
• In 2018, Lonza opened its Collaborative Innovation Center in Haifa, Israel.
• In 2018, Sartorius will offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing.
• In 2017, GE Healthcare acquired Asymptote (UK) in order to strengthen its cell therapy portfolio with a suite of technologies for the cryopreservation of cellular materials.

These markets boast comparatively lenient standards and government regulations as opposed to developed markets in North America and the EU, and thus offer significant growth potential for providers. However, the high cost of cell-based research and the low success rate is expected to restrain market growth to some extent during the forecast period.

Cell processing segment to witness the highest growth during the forecast period :
Based on process, the cell therapy technologies market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control. The cell processing segment is expected to account for the largest market share in 2018 and is projected to witness the highest CAGR during the forecasted period.

Browse and in-depth TOC on “Cell Therapy Technologies Market”
75 – Tables
30 – Figures
116 – Pages

To Get Sample Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978

Key players in this market include Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US).

Thermo Fisher was the largest player in the Cell Therapy Technologies Market in 2017. In order to maintain its position in the market and further expand its product portfolio, the company focuses on the strategies of product launches, acquisitions, and expansions. Merck holds the second position in the cell therapy technologies market. The company focuses on collaborations, agreements, and acquisitions to enhance its market position.

North America to dominate the cell therapy technologies market during the forecast period :
The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the market in 2018 owing to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries.

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=213334978

What Drives the Market?

The growth of the Cell Therapy Technologies Market is primarily influenced by the following factors:
• Rising Government Investments in Cell-Based Research
• Large Number of Oncology-Oriented Cell-Based Therapy Clinical Trials
• Affordability and Sustainability of Advanced Cell Therapy Instruments

About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain-points around revenues decisions.